Close Menu
Tamar BridgeTamar Bridge
  • Home
  • Latest News
  • About Us
    • Our Team
    • Join the team
  • Policies
    • Cookies
    • Terms & Conditions
    • Privacy Policy
  • Sitemap
  • —————–
  • Money
  • Tech
  • Lifestyle
  • News
  • Health
  • Property
  • Business
  • Travel
  • Motors
  • Contact Us
Facebook X (Twitter) LinkedIn
Facebook X (Twitter)
Tamar BridgeTamar Bridge
Contact
  • About Us
    • Our Team
    • Contact Us
    • Join the team
  • News
  • Culture
  • Money
  • Business
  • Health
  • Lifestyle
  • Tech
  • Motors
Tamar BridgeTamar Bridge
Home»Health»Kyowa Kirin reveals new CTCL study findings at EORTC meeting
Health

Kyowa Kirin reveals new CTCL study findings at EORTC meeting

Sam AllcockBy Sam Allcock08/10/20243 Mins Read

Kyowa Kirin International (KKI) has announced the upcoming presentation of interim findings from three significant real-world studies focusing on cutaneous T-cell lymphoma (CTCL) at the European Organisation for Research and Treatment of Cancer’s Cutaneous Lymphoma Tumour Group (EORTC-CLTG) annual meeting. The event is set to take place in Lausanne, Switzerland, from 9 to 11 October 2024.

These studies involve participants from Europe, the United States, and the United Arab Emirates, and aim to gather evidence regarding the effectiveness of mogamulizumab, a pioneering humanised monoclonal antibody therapy. This treatment is currently approved in Europe and the UAE for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have undergone at least one prior systemic therapy. In the US and Switzerland, mogamulizumab is also approved for adult patients with relapsed or refractory MF or SS.

Professor Emmanuella Guenova, Chief Physician of Dermatology and Venereology at Lausanne University Hospital and Chair of the EORTC-CLTG 2024 Annual Meeting, emphasised the importance of real-world evidence in guiding treatment decisions. “For most patients, treatment of CTCL aims to prolong time to disease progression, reduce the burden of disease, and preserve or enhance quality of life,” she noted. “The data being established by Kyowa Kirin is invaluable for physicians in understanding treatment responses in real-world settings.”

This presentation will showcase the second interim analyses from three ongoing studies:

  1. MINT (conducted in Germany) and MIBERIC (Spain and Portugal) are focused on evaluating the effectiveness and tolerability of mogamulizumab in clinical practice. The findings thus far align with the efficacy and safety data observed in global clinical trials, with no new safety signals reported across both studies.
  2. PROSPER, which includes participants from the US, UAE, Spain, Italy, the Netherlands, and the UK, investigates the impact of mogamulizumab from the patient’s perspective. The study assesses various symptoms and health-related quality of life (HRQoL), highlighting significant improvements in skin symptoms—including pain, itch, flaking, and redness—within four weeks of treatment. Moreover, improvements in patient-reported fatigue and overall HRQoL were reported within 24 weeks.

Dr Nicholas Kronfeld, Senior Vice President and Head of Medical Affairs at Kyowa Kirin International, stated, “The studies being presented at EORTC-CLTG build on our previous presentations and reinforce our commitment to providing the community with comprehensive real-world data. This will enhance clinical decision-making and aim to improve patient outcomes.”

Kyowa Kirin is dedicated to sharing scientific knowledge at the EORTC-CLTG 2024 meeting, with three accepted abstracts scheduled for presentation.

The presentations will include:

  • MINT Study: “Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study,” presented by Prof. Chalid Assaf on 9 October.
  • MIBERIC Study: “Real-world effectiveness of mogamulizumab in Spain and Portugal: Second interim analysis,” presented by Prof. Pablo Ortiz Romero on 9 October.
  • PROSPER Study: “Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results,” presented by Prof. Julia Scarisbrick on 10 October.

For further details about Kyowa Kirin and its research, visit Kyowa Kirin’s website.

ctcl eortc findings health kirin kyowa meeting new reveals study
Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
Previous ArticleI Hate Christmas (TV Series 2022– ) – User reviews
Next Article EDW Launches New AI-Enabled Data Access Platform EDVANCE

Other stories that may interest you

Amanda Kloots’ New Romance, Who is Her Boyfriend, Justin Gimelstob? The Unlikely Couple’s Red Carpet Debut

06/05/2025

Tammy Slaton’s New Love, Who Is Andrea, the Mysterious Girlfriend Winning Over 1000-Lb Sisters Fans?

24/04/2025

Zach Bryan’s New Flame? Inside His Rumored Romance with Hannah Duncan

18/04/2025

Latest Stories

TrendsFinGroup.com review – Is Trends Financial Group a trusted platform for Canadian traders?

08/05/2025

Paulo Avelino’s Girlfriend, The Untold Story Behind His Relationship with Kim Chiu

06/05/2025

Tim Duncan’s Girlfriend Vanessa Macias, The Hidden Gem Behind The NBA Legend’s Quiet Life

06/05/2025

Amanda Kloots’ New Romance, Who is Her Boyfriend, Justin Gimelstob? The Unlikely Couple’s Red Carpet Debut

06/05/2025
  • Facebook
  • Twitter
  • LinkedIn
Sections
  • News
  • Culture
  • Money
  • Business
  • Health
  • Lifestyle
  • Tech
  • Motors

Tamar Bridge News is your trusted guide through the currents of UK news, committed to bridging the gap between information and insight with clarity, precision, and a human-centric approach.

Company

  • Home
  • Latest News
  • About Us
  • Our Team
  • Contact Us
  • Join the team
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Sitemap

Latest Stories

TrendsFinGroup.com review – Is Trends Financial Group a trusted platform for Canadian traders?

By Sam Allcock

Paulo Avelino’s Girlfriend, The Untold Story Behind His Relationship with Kim Chiu

By Sam Allcock

Tim Duncan’s Girlfriend Vanessa Macias, The Hidden Gem Behind The NBA Legend’s Quiet Life

By Sam Allcock
© 2025 Tamar Bridge News | All rights reserved

Type above and press Enter to search. Press Esc to cancel.